These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


358 related items for PubMed ID: 28669410

  • 1. Thrombin activatable fibrinolysis inhibitor (TAFI) - A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS).
    Grosso G, Vikerfors A, Woodhams B, Adam M, Bremme K, Holmström M, Ågren A, Eelde A, Bruzelius M, Svenungsson E, Antovic A.
    Thromb Res; 2017 Oct; 158():168-173. PubMed ID: 28669410
    [Abstract] [Full Text] [Related]

  • 2. Monoclonal antibodies targeting the antifibrinolytic activity of activated thrombin-activatable fibrinolysis inhibitor but not the anti-inflammatory activity on osteopontin and C5a.
    Semeraro F, Ammollo CT, Gils A, Declerck PJ, Colucci M.
    J Thromb Haemost; 2013 Dec; 11(12):2137-47. PubMed ID: 24134522
    [Abstract] [Full Text] [Related]

  • 3. Increase in plasma thrombin-activatable fibrinolysis inhibitor may not contribute to thrombotic tendency in antiphospholipid syndrome because of inhibitory potential of antiphospholipid antibodies toward TAFI activation.
    Ieko M, Yoshida M, Naito S, Nakabayashi T, Kanazawa K, Mizukami K, Mukai M, Atsumi T, Koike T.
    Int J Hematol; 2010 Jun; 91(5):776-83. PubMed ID: 20490730
    [Abstract] [Full Text] [Related]

  • 4. Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
    Antovic JP, Blombäck M.
    Thromb Res; 2002 Apr 01; 106(1):59-62. PubMed ID: 12165290
    [Abstract] [Full Text] [Related]

  • 5. Thrombin activatable fibrinolysis inhibitor (TAFI): a molecular link between coagulation and fibrinolysis.
    Miljić P, Heylen E, Willemse J, Djordjević V, Radojković D, Colović M, Elezović I, Hendriks D.
    Srp Arh Celok Lek; 2010 Jan 01; 138 Suppl 1():74-8. PubMed ID: 20229688
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation.
    Myles T, Nishimura T, Yun TH, Nagashima M, Morser J, Patterson AJ, Pearl RG, Leung LL.
    J Biol Chem; 2003 Dec 19; 278(51):51059-67. PubMed ID: 14525995
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effect of warfarin treatment on thrombin activatable fibrinolysis inhibitor (TAFI) activation and TAFI-mediated inhibition of fibrinolysis.
    Incampo F, Carrieri C, Galasso R, Scaraggi FA, Di Serio F, Woodhams B, Semeraro N, Colucci M.
    J Thromb Haemost; 2013 Feb 19; 11(2):315-24. PubMed ID: 23256818
    [Abstract] [Full Text] [Related]

  • 13. Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles.
    Boffa MB, Koschinsky ML.
    Clin Biochem; 2007 Apr 19; 40(7):431-42. PubMed ID: 17331488
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A.
    Antovic J, Schulman S, Eelde A, Blombäck M.
    Haemophilia; 2001 Nov 19; 7(6):557-60. PubMed ID: 11851753
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 18.